{
  "name": "Lorazepam",
  "genericName": "lorazepam",
  "brandNames": ["Ativan"],
  "tags": ["Benzodiazepine", "Anxiolytic"],
  "dosing": {
    "adult_acute": "Anxiety: 0.5-2 mg BID-TID PRN; Agitation: 1-2 mg IM/IV q4-6h PRN",
    "adult_maintenance": "2-6 mg/day divided BID-TID for short-term use only",
    "notes": "Intermediate-acting; no active metabolites; IM/IV/SL/PO formulations; preferred in elderly and hepatic impairment",
    "canadian_clinical": {
      "starting_dose": "0.5-1 mg BID-TID PRN",
      "titration_schedule": "Titrate to minimum effective dose; avoid regular dosing if possible",
      "max_dose_evidence": "10 mg/day",
      "max_dose_practice": "4-6 mg/day; use lowest effective dose for shortest duration",
      "inpatient_strategy": "Agitation: 1-2 mg IM/PO q4-6h PRN; Alcohol withdrawal: Higher doses protocol-driven",
      "outpatient_strategy": "0.5-1 mg PRN for anxiety; educate on dependence risk; time-limited use"
    }
  },
  "warnings": [
    "Black box warning: (1) Concomitant use with opioids may result in respiratory depression, coma, death; (2) Abuse, misuse, addiction; (3) Dependence and withdrawal",
    "Physical dependence develops with regular use (can occur within 2-4 weeks)",
    "Withdrawal can be life-threatening - taper slowly",
    "Cognitive impairment, sedation, falls (especially elderly)",
    "Paradoxical disinhibition possible",
    "Avoid in pregnancy (cleft palate risk) and breastfeeding",
    "Should be SHORT-TERM use only (<2-4 weeks); not for chronic anxiety management"
  ],
  "cautions": {
    "renal": "No adjustment needed (no active metabolites) - preferred benzodiazepine in renal impairment",
    "hepatic": "No adjustment (glucuronidation, no active metabolites) - preferred benzodiazepine in hepatic impairment",
    "pregnancy": "Pregnancy Category D - avoid; associated with cleft palate"
  },
  "citations": ["Ativan FDA Label", "NICE Anxiety Guidelines", "Benzodiazepine Deprescribing Guidelines"]
}
